Andrew W. Michell

TL;DR: A distinctive seizure semiology is described that closely associates with voltage‐gated potassium channel (VGKC)‐complex/Lgi1 antibodies and commonly precedes the onset of limbic encephalitis (LE).

TL;DR: In this paper, mesenchymal stem cells were used as a potential neuroprotective treatment for secondary progressive multiple sclerosis (SMS) in 10 patients from the East Anglia and North London regions of the UK.

TL;DR: The current potential biomarkers for Parkinson's disease are discussed, the problems with their use are highlighted, and a discussion of future alternatives are concluded.

TL;DR: The data raise the prospect of a robust molecular definition of progression of HD prior to symptom onset, and if validated in a genuinely prospective fashion these biomarker trajectories could facilitate the development of useful therapies for this disease.

TL;DR: The MSCIMS trial tests the safety and feasibility of treatment with a candidate cell-based therapy, and will inform the wider challenge of designing early phase clinical trials to evaluate putative neuroprotective therapies in progressive MS.